 Chelsea Therapeutics International Ltd. said Tuesday that the U.S. Food and Drug Administration granted accelerated approval of Northera, its treatment of symptomatic neurogenic orthostatic hypotension..  Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops products for the treatment of a variety of human diseases, including central nervous system disorders. The accelerated approval mechanism is aimed at speeding drugs to market. 